Adam Rauckhorst

Dr. Adam Rauckhorst

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Cell Metabolism
Verified
Journal Article
Closed access
LGLawrence R. Gray
Lawrence R. Gray
MSMst Rasheda Sultana
Mst Rasheda Sultana
ARAdam Rauckhorst
Adam Rauckhorst
LOLalita Oonthonpan
Lalita Oonthonpan
STSean C. Tompkins
Sean C. Tompkins
ETEric Taylor
Eric Taylor

26 October 2020 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
YZYuan Zhang
Yuan Zhang
PTPaul V. Taufalele
Paul V. Taufalele
JCJesse D. Cochran
Jesse D. Cochran
IRIsabelle Robillard-Frayne
Isabelle Robillard-Frayne
JMJonas Maximilian Marx
Jonas Maximilian Marx
EAE. Dale Abel
E. Dale Abel

1 November 2017 in Molecular Metabolism
Verified
Journal Article
Open access
ARAdam Rauckhorst
Adam Rauckhorst
LGLawrence R. Gray
Lawrence R. Gray
RSRyan Shedon
Ryan Shedon
XFXiaorong Fu
Xiaorong Fu
APAlvin D. Pewa
Alvin D. Pewa
ETEric Taylor
Eric Taylor
Excessive hepatic gluconeogenesis is a defining feature of type 2 diabetes (T2D). Most gluconeogenic flux is routed through mitochondria. The mitochondrial pyruvate carrier (MPC) transports pyruvate from the cytosol into the mitochondrial matrix, thereby gating pyruvate-driven gluconeogenesis. Disruption of the hepatocyte MPC attenuates hyperglycemia in mice during high fat diet (HFD)-induced obesity but exerts minimal effects on glycemia in normal chow diet (NCD)-fed conditions. The goal of this investigation was to test whether hepatocyte MPC disruption provides sustained protection from hyperglycemia during long-term HFD and the differential effects of hepatocyte MPC disruption on TCA cycle metabolism in NCD versus HFD conditions. We utilized long-term high fat feeding, serial measurements of postabsorptive blood glucose and metabolomic profiling and 13C-lactate/13C-pyruvate tracing to investigate the contribution of the MPC to hyperglycemia and altered hepatic TCA cycle metabolism during HFD-induced obesity. Hepatocyte MPC disruption resulted in long-term attenuation of hyperglycemia induced by HFD. HFD increased hepatic mitochondrial pyruvate utilization and TCA cycle capacity in an MPC-dependent manner. Furthermore, MPC disruption decreased progression of fibrosis and levels of transcript markers of inflammation. By contributing to chronic hyperglycemia, fibrosis, and TCA cycle expansion, the hepatocyte MPC is a key mediator of the pathophysiology induced in the HFD model of T2D.

18 July 2019 in eLife
Verified
Journal Article
Open access
ASArpit Sharma
Arpit Sharma
LOLalita Oonthonpan
Lalita Oonthonpan
RSRyan Shedon
Ryan Shedon
ARAdam Rauckhorst
Adam Rauckhorst
ZZZhiyong Zhu
Zhiyong Zhu
ETEric Taylor
Eric Taylor
Metabolic cycles are a fundamental element of cellular and organismal function. Among the most critical in higher organisms is the Cori Cycle, the systemic cycling between lactate and glucose. Here, skeletal muscle-specific Mitochondrial Pyruvate Carrier (MPC) deletion in mice diverted pyruvate into circulating lactate. This switch disinhibited muscle fatty acid oxidation and drove Cori Cycling that contributed to increased energy expenditure. Loss of muscle MPC activity led to strikingly decreased adiposity with complete muscle mass and strength retention. Notably, despite decreasing muscle glucose oxidation, muscle MPC disruption increased muscle glucose uptake and whole-body insulin sensitivity. Furthermore, chronic and acute muscle MPC deletion accelerated fat mass loss on a normal diet after high fat diet-induced obesity. Our results illuminate the role of the skeletal muscle MPC as a whole-body carbon flux control point. They highlight the potential utility of modulating muscle pyruvate utilization to ameliorate obesity and type 2 diabetes.

1 June 2016 in Current Opinion in Genetics & Development
Verified
Journal Article
Closed access
ARAdam Rauckhorst
Adam Rauckhorst
ETEric Taylor
Eric Taylor

1 January 2019 in Cellular and Molecular Gastroenterology and Hepatology
Verified
Journal Article
Open access
QQQingwen Qian
Qingwen Qian
ZZZeyuan Zhang
Zeyuan Zhang
MLMark Li
Mark Li
KSKalie Savage
Kalie Savage
DCDechun Cheng
Dechun Cheng
LYLing Yang
Ling Yang
The lysosome is an acidic organelle that is important for maintaining cellular and metabolic homeostasis in hepatocytes. Lysosomal dysfunction and chronic inflammation coexist, and both contribute to obesity-associated hepatic insulin resistance. However, in the context of obesity, the interplay between inflammatory signals and hepatic lysosomal function remains largely unknown. Inducible nitric oxide synthase (iNOS) is a hallmark for inflammation, and is activated in obesity. The aim of this study is to understand the molecular link between iNOS-mediated lysosomal nitric oxide (NO) production, hepatic lysosomal function, and autophagy in the context of obesity-associated insulin resistance. The role of iNOS in hepatic autophagy, as related to insulin and glucose homeostasis were studied in mice with diet-induced obesity (DIO). The effects and mechanisms of iNOS-mediated lysosomal NO production on lysosomal function and hepatic autophagy were studied in primary hepatocytes as well as in a mouse model of DIO. We demonstrate that obesity promotes iNOS localization to the lysosome and decreases levels of lysosomal arginine, resulting in an accumulation of NO in hepatic lysosomes. This lysosomal NO production is attenuated by treatment with a NO scavenger, while co-overexpression of mTOR and a lysosomal arginine transporter (SLC38A9) enhances lysosomal NO production and suppresses autophagy. In addition, we show that deletion of iNOS ameliorates lysosomal nitrosative stress in the livers of DIO mice, promotes lysosomal biogenesis by activating transcription factor EB (TFEB), and enhances lysosomal function and autophagy. Lastly, deletion of iNOS in mice with DIO improves hepatic insulin sensitivity, which is diminished by suppression of TFEB or autophagy related 7 (Atg7). Our studies suggest that lysosomal iNOS-mediated NO signaling disrupts hepatic lysosomal function, contributing to obesity-associated defective hepatic autophagy and insulin resistance.